Clinicopathological features of adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
12 01 2021
12 01 2021
Historique:
received:
17
08
2020
accepted:
20
11
2020
entrez:
11
2
2021
pubmed:
12
2
2021
medline:
15
5
2021
Statut:
ppublish
Résumé
Hodgkin and Reed-Sternberg (HRS) cells, a hallmark of classic Hodgkin lymphoma (CHL), are occasionally detected in non-Hodgkin lymphomas, including adult T-cell leukemia/lymphoma (ATLL), a lymphoid neoplasm caused by human T-cell leukemia virus type 1 (HTLV-1). HRS-like cells associated with ATLL have been described to be of B-cell lineage and infected with Epstein-Barr virus (EBV), not HTLV-1. We herein describe clinicopathological findings in 8 cases (4 males and 4 females; median age, 73 years [range, 55-81 years]) of ATLL with HTLV-1-infected HRS-like cells identified by ultrasensitive RNA in situ hybridization for HTLV-1 basic leucine zipper factor (HBZ-ISH), a specific viral transcript of HTLV-1. All patients showed nodal or mediastinal lesions, and 5 of the 8 patients were at an advanced disease stage. HRS-like cells were positive for CD30, CD15, MUM1, CD25, and HBZ-ISH and negative for B-cell markers, including PAX5, pan-T-cell antigens, and EBV in all cases. Five cases were positive for CD4, and 6 cases were positive for fascin. HBZ was identified in both HRS-like cells and surrounding lymphoid cells in 1 case with an aggressive clinical course and only HRS-like cells in 7 cases, most of whom showed a clinical response regardless of the chemotherapeutic regimen. Even though the definitive lineage typing of the HTLV-1-infected HRS cells is one of the limitations of this study in the absence of single-cell microdissection for polymerase chain reaction analysis, the combination of diffuse HBZ-ISH positivity and negativity for PAX5 and EBV deemed these cases distinct from CHL arising in HTLV-1 carriers.
Identifiants
pubmed: 33570645
pii: S2473-9529(21)00019-7
doi: 10.1182/bloodadvances.2020003201
pmc: PMC7805330
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
198-206Informations de copyright
© 2021 by The American Society of Hematology.
Références
Cancer. 1991 Mar 15;67(6):1622-8
pubmed: 2001551
Am J Surg Pathol. 2019 Dec;43(12):1611-1621
pubmed: 31305266
Am J Surg Pathol. 2010 Sep;34(9):1382-7
pubmed: 20739840
Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7
pubmed: 6326131
Blood. 2000 May 15;95(10):3020-4
pubmed: 10807764
J Clin Oncol. 2012 May 10;30(14):1635-40
pubmed: 22473153
Am J Surg Pathol. 2003 Dec;27(12):1513-22
pubmed: 14657710
Mod Pathol. 2008 May;21(5):617-25
pubmed: 18246047
Cancer Sci. 2007 Jun;98(6):772-8
pubmed: 17388788
Br J Haematol. 1991 Nov;79(3):428-37
pubmed: 1751370
Mod Pathol. 2011 Aug;24(8):1046-54
pubmed: 21499229
Am J Surg Pathol. 2007 Feb;31(2):216-23
pubmed: 17255766
Diagn Mol Pathol. 2002 Jun;11(2):83-9
pubmed: 12045711
Am J Surg Pathol. 1999 Oct;23(10):1233-40
pubmed: 10524524
Br J Haematol. 2014 Sep;166(5):739-48
pubmed: 24931507
Mod Pathol. 2021 Jan;34(1):51-58
pubmed: 32801340
Cancer Sci. 2019 Sep;110(9):2982-2991
pubmed: 31237072
J Exp Med. 2000 Jan 17;191(2):387-94
pubmed: 10637283
Am J Surg Pathol. 2012 Dec;36(12):1874-82
pubmed: 23060353
Int J Cancer. 1997 Aug 7;72(4):592-8
pubmed: 9259396
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Blood. 2020 Jul 9;136(2):257
pubmed: 32645171
Mod Pathol. 2018 Jul;31(7):1046-1063
pubmed: 29449683
Histopathology. 2012 Apr;60(5):768-73
pubmed: 22296097
Braz J Infect Dis. 2017 Jan - Feb;21(1):119-122
pubmed: 27789281
Blood. 2013 Mar 7;121(10):1795-804
pubmed: 23305738
Am J Surg Pathol. 2012 Nov;36(11):1636-46
pubmed: 23073322
Blood. 2013 Oct 17;122(16):2856-63
pubmed: 24004665
Histopathology. 2020 Jul;77(1):133-143
pubmed: 32162348
Hum Pathol. 2011 Jul;42(7):1042-6
pubmed: 21315416